Loading...

Kazia Therapeutics Limited

KZA.AX•ASX
Healthcare
Biotechnology
A$0.08
A$0.007(9.59%)

Kazia Therapeutics Limited (KZA.AX) Company Profile & Overview

Explore Kazia Therapeutics Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Kazia Therapeutics Limited (KZA.AX) Company Profile & Overview

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

SectorHealthcare
IndustryBiotechnology
CEOJohn E. Friend II,

Contact Information

https://www.kaziatherapeutics.com
1161298780088
Three International Towers, Sydney, NSW, 2000

Company Facts

12 Employees
IPO DateSep 30, 1994
CountryAU

Frequently Asked Questions

;